BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 27, 2025
Home » Authors » Omar Ford

Omar Ford

Articles

ARTICLES

SEMDA 2015: TriNet's Goldfield looking for vision, technology when making acquisitions

April 2, 2015
By Omar Ford

SEMDA 2015: Data, regulatory hurdles dominate first day of SEMDA conference

April 1, 2015
By Omar Ford

AAOS 2015: Syncera changes paradigm of orthopedic sales model

March 31, 2015
By Omar Ford

LAS VEGAS — Just across from Smith & Nephew's (S&N; London) 90X100 makeshift office on the exhibit floor at the American Academy of Orthopedic Surgeons (Rosemont, Illinois) annual meeting – lies Syncera (Mansfield, Massachusetts), a business unit set to change the model of how orthopedic products are sold.


Read More

AAOS 2015: Cayenne Medical releases 2-year results of Mirror Partial Knee study

March 30, 2015
By Omar Ford

AAOS 2015 conference: Value over volume is the new shift in treating patients

March 30, 2015
By Omar Ford

LAS VEGAS — Reimbursement. Physician pay. Value over volume. All are words that were pretty common at the American Association of Orthopedic Surgeons (AAOS; Rosemont Illinois), annual meeting held last week at the Venetian/Sands EXPO in Las Vegas.


Read More

MDD's Diagnostics Extra

March 27, 2015
By Omar Ford

AAOS 2015: Bioventus establishes its identity, products in ortho-biologics space

March 27, 2015
By Omar Ford

LAS VEGAS — Three years ago, Smith & Nephew (S&N; London) spun off its biologics unit in partnership with Woodlands Essex to form Bioventus (Durham, North Carolina). Fast forward to today, and Bioventus is maintaining a global presence in the biologics market, with about 500 employees strong, and nearly $240 million dollars in yearly revenue.


Read More

AAOS 2015 Meeting: Depuy reaffirms R&D commitment, introduces new products at AAOS

March 26, 2015
By Omar Ford

LAS VEGAS — Nearly four years ago, Johnson & Johnson (J&J;New Brunswick, New Jersey) revealed its intent to acquire Synthes (Solothurn, Switzerland), a firm that develops surgical devices used to treat fractures and traumatic injuries for $21.3 billion. Synthes, has now been carefully folded into J&J's Depuy (Warsaw, Indiana).


Read More

AAOS 2015 Annual Meeting: AAOS panel talks bridging the gap in technological advances in healthcare

March 25, 2015
By Omar Ford

Teleflex hoping Percuvance paves way for category of percutaneous surgery

March 24, 2015
By Omar Ford
View All Articles by Omar Ford

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing